aid: exscientia
name: Exscientia
description: >-
  Exscientia was an Oxford UK-based AI-driven precision medicine and drug
  design company, founded in 2012 as a spin-out from the University of Dundee.
  Its platform combined generative chemistry (Centaur Chemist) with patient
  tissue-based screening (EVE, an automated single-cell platform for testing
  drug candidates directly against patient-derived tumor samples) to design
  small-molecule drug candidates faster and at lower cost than conventional
  pharma R&D. Notable firsts included EXS-21546 (an A2A antagonist developed
  with Evotec), DSP-1181 (the first AI-designed molecule to enter human
  clinical trials, with Sumitomo Dainippon Pharma), and DSP-0038 (a dual
  5-HT1A/5-HT2A modulator for Alzheimer's psychosis). Exscientia maintained
  active pharma partnerships with Sanofi, Bristol Myers Squibb, Bayer,
  Sumitomo, and Merck KGaA. Exscientia was acquired by Recursion
  Pharmaceuticals (NASDAQ: RXRX) in an all-stock deal that closed in
  November 2024; the combined company operates under the Recursion brand and
  the legacy exscientia.ai website now redirects to recursion.com. The
  Exscientia name persists primarily through its GitHub organization, which
  continues to host open-source scientific Python packages for molecular
  predictive modelling (molflux), physics-based ML potentials (physicsml),
  antibody structure prediction (abodybuilder3), and biomolecular simulation
  (biosimspace) used by the wider computational chemistry and structural
  biology community. Exscientia did not expose any public commercial APIs,
  SDKs, or developer products before or after the merger; platform access was
  always delivered through collaborative drug-discovery agreements.
type: Index
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/apis-json-logo.jpg
tags:
  - Drug Discovery
  - Drug Design
  - AI Drug Design
  - Precision Medicine
  - Biotech
  - Pharmaceuticals
  - Generative Chemistry
  - Centaur Chemist
  - EVE Platform
  - Patient-Derived Screening
  - Oncology
  - Small Molecules
  - Computational Chemistry
  - Machine Learning
  - Open Source
  - Acquired
url: https://raw.githubusercontent.com/api-evangelist/exscientia/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
  - type: DomainSecurity
    url: security/exscientia-domain-security.yml
  - type: Website
    url: https://www.recursion.com
  - type: LegacyWebsite
    url: https://www.exscientia.ai
  - type: AcquisitionAnnouncement
    url: https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-combine-create-leading-techbio-company
  - type: AcquisitionClosing
    url: https://ir.recursion.com/news-releases/news-release-details/recursion-completes-business-combination-exscientia
  - type: ParentCompany
    url: https://www.recursion.com
  - type: GitHubOrganization
    url: https://github.com/Exscientia
  - type: Molflux
    url: https://github.com/Exscientia/molflux
  - type: PhysicsML
    url: https://github.com/Exscientia/physicsml
  - type: ABodyBuilder3
    url: https://github.com/Exscientia/abodybuilder3
  - type: BioSimSpace
    url: https://github.com/Exscientia/biosimspace
  - type: StableNetGuardOwl
    url: https://github.com/Exscientia/StableNetGuardOwl
  - type: RDVC
    url: https://github.com/Exscientia/rdvc
  - type: Wikipedia
    url: https://en.wikipedia.org/wiki/Exscientia
  - type: Crunchbase
    url: https://www.crunchbase.com/organization/exscientia
  - type: LinkedIn
    url: https://www.linkedin.com/company/exscientialtd
maintainers:
  - FN: Kin Lane
    email: kin@apievangelist.com